Show an ad over header. AMP

The risks of moving too fast on a coronavirus vaccine

The scientific race for a coronavirus vaccine is moving at record-shattering speed. Making the most of that work — translating a successful clinical product into real-world progress — will require some patience.

Why it matters: If we get a vaccine relatively soon, the next big challenge will be balancing the need to get it into people's hands with the need to keep working on other solutions that might prove more effective.


Where it stands: Eight potential vaccines are in late-stage clinical trials. The first one could be submitted for FDA review as early as October or November, and several more could follow within just a few months.

  • The FDA has already laid out its standards for potential vaccines: They have to be safe, and they have to reduce the chance of moderate to severe infection by at least 50%.
  • That’s a relatively modest bar, but experts say it’s an appropriate one, especially in an emergency.

But the fear is that the understandable desire to get a safe, effective vaccine into people’s veins as fast as possible could make a better or more targeted vaccine harder to come by.

  • “My concern is that you want to get it right the first time, whatever you [authorize] first, because it’s really going to change the landscape,” said Natalie Dean, a biostatistician at the University of Florida who specializes in the design of clinical trials for vaccines.

How it works: We know the coronavirus affects different people in different ways. So, ideally, we’d want to know how well each vaccine works in people with the most significant risk factors.

  • “We may not have a lot of that coming out of these trials. They’re certainly not powered to address these subgroup-specific effects,” Dean said.
  • “If we don't have adequate data in the greater-than-65-year-old group, then the greater-than-65-year-old person shouldn't get this vaccine, which would be a shame because they're the ones who are most likely to die from this infection,” vaccine expert Paul Offit said in a recent conversation with scientist Eric Topol.
  • The FDA will be looking for evidence of how well each vaccine works in the overall population, so that’s the question their clinical trials are set up to answer.

What they’re saying: One of the most important things regulators and vaccine developers can do right now, experts said, is to generate as much data as possible while clinical trials are still under way.

  • They won’t have another chance to run more clinical trials just to study how the vaccines work for narrower groups of people. So whatever questions we need to answer in the future, they’ll have to be answered with today’s data.
  • “This is our chance to learn whether something works,” Dean said. “You can’t go backwards.”

Yes, but: Pfizer and Moderna, which are developing two of the leading candidates, have each signed up some 30,000 people for their trials, but have said they’ll do interim analyses with results from fewer than 50 people.

  • If those results are strong enough, the trials could end early.
  • And once there’s a single effective vaccine, it’s harder to maintain other placebo-controlled studies. Researchers will face an ethical dilemma about whether to keep giving people a placebo, Dean said, and people are less likely to sign up for a trial, and risk a placebo, if they think they can just get a vaccine from their doctor.

The other side: The regulatory process, along with some of the logistical hurdles that make vaccine distribution so difficult, can help with some of this.

  • Only a handful of doses will be ready once the first vaccine is authorized. If the second vaccine comes through a short time later and turns out to be wildly more effective, there will be time to adjust.
  • Several of the leading candidates require two shots, and some must be stored at temperatures as low as -20 degrees Fahrenheit. A vaccine that’s moderately less effective but also less fussy might be worth the trade-off, at least for some patients.

The big picture: These are all issues that need to be managed within a historically fast process; they are not indictments of moving fast. They are in many ways good problems to have.

  • “Wouldn’t it be great if we’re in a position if we have, say, 2-5 safe and effective vaccines?” said Dan Barouch, the director of Harvard’s Center for Virology and Vaccine Research. "If more than one vaccine shows safety and efficacy, then we actually would welcome that result."

Iran's nuclear dilemma: Ramp up now or wait for Biden

The world is waiting to see whether Iran will strike back at Israel or the U.S. over the assassination of Mohsen Fakhrizadeh, the architect of Iran's military nuclear program.

Why it matters: Senior Iranian officials have stressed that Iran will take revenge against the perpetrators, but also respond by continuing Fakhrizadeh’s legacy — the nuclear program. The key question is whether Iran will accelerate that work now, or wait to see what President-elect Biden puts on the table.

Keep reading... Show less

U.K. clears Pfizer-BioNTech coronavirus vaccine for mass rollout

The United Kingdom became on Wednesday the first Western country in the world to license the Pfizer/BioNTech COVID-19 vaccine for widespread use.

What they're saying: "Today’s emergency use authorisation in the UK marks a historic moment in the fight against COVID-19," said Albert Bourla, the chairman and chief executive officer of Pfizer, per the Guardian.

  • "This authorisation is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the UK."

Editor's note: This a breaking news story. Please check back for updates.

Biden tells NYT he won't immediately remove U.S. tariffs on China

President Trump's 25% tariffs imposed on China under the phase one trade deal will remain in place at the start of the new administration, President-elect Biden said in an interview with the New York Times published early Wednesday.

Details: "I'm not going to make any immediate moves, and the same applies to the tariffs," Biden said. He plans to conduct a full review of the current U.S. policy on China and speak with key allies in Asia and Europe to "develop a coherent strategy," he said.

Keep reading... Show less

Trump threatens to veto Defense spending bill over social media shield

President Trump tweeted Tuesday a threat to veto a must-pass end-of-year $740 billion bill defense-spending authorization bill unless Conress repeals a federal law that protects social media sites from legal liability.

Why it matters: Trump's attempt to get Congress to end the tech industry protections under Section 230 of the Communications Decency Act is the latest escalation in his war on tech giants over what he and some other Republicans perceive as bias against conservatives.

Keep reading... Show less

The walls close in on Trump

With Bill Barr's "Et tu, Brute!" interview with AP, President Trump is watching the walls close in on his claims of fraud, hoaxes and conspiracies.

Why it matters: Trump and his legal team continue to claim election fraud. But the Republican governors of Arizona and Georgia have certified their elections, a loyalist like Barr has weighed in, and lower-ranking officials have taken potshots.

Keep reading... Show less

Congress plots COVID pandemic-era office upgrades

The House plans to renovate members' suites even though staff are worried about an influx of contractors and D.C. is tightening restrictions on large gatherings, some staffers told Axios.

Why it matters: The Capitol has been closed to public tours since March. Work over the holiday season comes as U.S. coronavirus cases spike, Americans beg for more pandemic assistance and food lines grow.

Keep reading... Show less

Trump applies extreme pressure on Bill Barr to release so-called Durham Report

President Trump and his allies are piling extreme pressure on Attorney General Bill Barr to release a report that Trump believes could hurt perceived Obama-era enemies — and view Barr's designation of John Durham as special counsel as a stall tactic, sources familiar with the conversations tell Axios.

Why it matters: Speculation over Barr's fate grew on Tuesday, with just 49 days remaining in Trump's presidency, after Barr gave an interview to the Associated Press in which he said the Justice Department has not uncovered evidence of widespread fraud that could change the election's outcome.

Keep reading... Show less

CDC to cut guidance on quarantine period for coronavirus exposure

The CDC will soon shorten its guidance for quarantine periods following exposure to COVID-19, AP reported Tuesday and Axios can confirm.

Why it matters: Quarantine helps prevent the spread of the coronavirus, which can occur before a person knows they're sick or if they're infected without feeling any symptoms. The current recommended period to stay home if exposed to the virus is 14 days. The CDC plans to amend this to 10 days or seven with a negative test, an official told Axios.

  • The CDC did not immediately respond to a request for comment.

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories